Page last updated: 2024-11-07

mozavaptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mozavaptan is a selective vasopressin V2 receptor antagonist. It was synthesized as a potential treatment for hyponatremia, a condition characterized by low blood sodium levels. Mozavaptan is thought to work by blocking the action of vasopressin, a hormone that helps the body retain water. By blocking the V2 receptor, mozavaptan prevents vasopressin from signaling the kidneys to conserve water. This can help to increase urine output and reduce water retention. Mozavaptan is being studied for its potential to treat hyponatremia in patients with heart failure, cirrhosis, and other conditions. Its importance lies in its potential to address the complications associated with hyponatremia. Research on mozavaptan is driven by the need for safe and effective treatments for hyponatremia, which can be a life-threatening condition. '

mozavaptan: aquaretic agent; vasopressin V2 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119369
CHEMBL ID420762
CHEBI ID135694
SCHEMBL ID1649322
MeSH IDM0554014

Synonyms (54)

Synonym
137975-06-5
AC-4255
mozavaptane
gtpl2197
n-[4-(5-dimethylamino2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
opc-31260
benzamide, n-(4-((5-(dimethylamino)-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)carbonyl)phenyl)-2-methyl-
mozavaptan
opc 31260
5-dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1h-benzazepine
n-(4-(((5rs)-5-(dimethylamino)-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide
mozavaptan [inn]
n-(4-((5-(dimethylamino)-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide
opc31260
CHEBI:135694
bdbm35714
n-[4-(5-dimethylamino-2,3,4,5-tetrahydro-benzo[b]azepine-1-carbonyl)-phenyl]-2-methyl-benzamide
chembl420762 ,
L001435
FT-0652996
n-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]phenyl]-2-methylbenzamide
A807320
n-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-oxomethyl]phenyl]-2-methylbenzamide
n-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-benzamide
unii-17oj42922y
17oj42922y ,
AKOS015895761
S2920
tox21_113926
dtxcid9031430
cas-137975-06-5
NCGC00262931-01
dtxsid8057641 ,
mozavaptan [mi]
mozavaptan [who-dd]
mozavaptan [mart.]
SCHEMBL1649322
benzamide, n-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-
c27h29n3o2
Q-101868
n-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1h-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide
EX-A1127
opc31260l
mfcd00908918
NCGC00262931-02
HY-18346
CS-6286
BCP06718
137975-06-5 (free base)
mozavaptan free base
AS-35085
Q12746116
SB18801
CCG-268974

Research Excerpts

Overview

Mozavaptan is a nonpeptide vasopressin receptor antagonist. It is approved for the treatment of ectopic antidiuretic hormone secretion syndrome.

ExcerptReferenceRelevance
"Mozavaptan is a nonpeptide vasopressin receptor antagonist approved for the treatment of ectopic antidiuretic hormone secretion syndrome."( UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.
Al-Rashood, KA; Asiri, Y; El-Nahhas, T; Ezzeldin, E; Iqbal, M; Mostafa, GA, 2018
)
2.18

Pharmacokinetics

ExcerptReferenceRelevance
"The method was effectively applied for the determination of mozavaptan pharmacokinetic parameters after the oral administration of 3 mg/kg mozavaptan in rats."( UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats.
Al-Rashood, KA; Asiri, Y; El-Nahhas, T; Ezzeldin, E; Iqbal, M; Mostafa, GA, 2018
)
0.98

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for AVP was shifted to the right in parallel by OPC-31260 but not by OPC-21268."( Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
Chiba, S; Tsukada, M, 1992
)
0.28
" Effects of the first dose of OPC-31260 and of a dose administered after a continuous dosing period of 12 days are reported."( Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
Fleeman, LM; Irwin, PJ; Phillips, PA; West, J, 2000
)
0.31
"Our results suggest that intervention with V2RA should be instituted early in ADPKD and that it might be necessary to further increase the dosage of this drug later in the disease to decrease cyst growth."( Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
de Heer, E; de Jong, PE; de Krey, SR; Gansevoort, RT; Leonhard, WN; Meijer, E; Mulder, GM; Peters, DJ; Struck, J; van den Born, J; van der Wal, AM; van Goor, H, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
aquareticA class of diuretics which promote aquaresis (the excretion of water without electrolyte loss).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.33320.006038.004119,952.5996AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency11.45110.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency12.75800.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency3.75780.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.43560.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.05500.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.86480.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.64590.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency0.29850.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.78010.000229.305416,493.5996AID1259248
caspase-3Homo sapiens (human)Potency3.75780.013326.981070.7614AID1346978
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency5.95530.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)IC50 (µMol)0.63730.00001.12137.0000AID1799335; AID217388
Vasopressin V2 receptorHomo sapiens (human)Ki0.00960.00040.43453.9811AID217521; AID703464
Oxytocin receptorHomo sapiens (human)Ki0.66000.00010.07180.9780AID703463
Vasopressin V1a receptorRattus norvegicus (Norway rat)IC50 (µMol)3.20000.08201.04775.0000AID217052; AID217226
Vasopressin V1a receptorHomo sapiens (human)IC50 (µMol)1.13730.00060.38352.0000AID1799335; AID216936
Vasopressin V1a receptorHomo sapiens (human)Ki0.19500.00020.62357.0300AID703465
Vasopressin V1b receptorHomo sapiens (human)IC50 (µMol)2.00002.00002.00002.0000AID216936
Vasopressin V1b receptorRattus norvegicus (Norway rat)IC50 (µMol)5.00005.00005.00005.0000AID217052
Vasopressin V2 receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.01200.00050.06380.5700AID217680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1b receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1b receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1b receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityVasopressin V1b receptorHomo sapiens (human)
regulation of cell population proliferationVasopressin V1b receptorHomo sapiens (human)
positive regulation of MAPK cascadeVasopressin V1b receptorHomo sapiens (human)
symbiont entry into host cellVasopressin V1b receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processVasopressin V1b receptorHomo sapiens (human)
positive regulation of arachidonic acid secretionVasopressin V1b receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1b receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1b receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1b receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1b receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1b receptorHomo sapiens (human)
peptide bindingVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endosomeVasopressin V1b receptorHomo sapiens (human)
Golgi apparatusVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID181609Antagonistic effect against Vasopressin V2 at 10 mg/kg dosed (ip) into rat with 0.4 ug/kg of AVP (in peanut oil); positive1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID191004Urine volume collected after 1 mg/kg of drug administration into 2 rats.1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID217052Inhibitory activity against arginine vasopressin V1 receptor using [3H]AVP as radioligand in rat liver1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID703460Agonist activity at human vasopressin V2 receptor expressed in CHO cells assessed as cAMP accumulation after 30 mins by TR-FRET based HTRF assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID217685Inhibitory activity against arginine vasopressin V2 receptor using [3H]AVP as radioligand in rat adrenal medulla1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID703463Binding affinity to oxytocin receptor2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID181615Antagonistic effect against Vasopressin V2 at 3 mg/kg dosed (ip) into rat with 0.4 ug/kg of AVP (in peanut oil); positive1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID224797UV values mean 2-h urine volume (mL) when the compound was administered orally at a dose of 10 mg/kg1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
AID191000Urine volume collected after 10 mg/kg of drug administration into 2 rats.1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID181612Antagonistic effect against Vasopressin V2 at 3 mg/kg administered orally (by gavage) 30 mL/kg of deionized water; positive1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID217680Displacement of [3H]-AVP from its AVP-V2 receptor binding site in rat kidney1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
AID181606Antagonistic effect against Vasopressin V2 at 10 mg/kg administered orally (by gavage) 30 mL/kg of deionized water; positive1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID216936Inhibitory activity against arginine vasopressin V1 receptor using [3H]AVP as radioligand in human platelet1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID179604Antagonistic effect against AVP-induced hypertension in rats after intravenous administration1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID217388Inhibitory activity against human recombinant arginine vasopressin V2 receptor using [3H]AVP as radioligand in CHO cells1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID217521Concentration which inhibit [3H]AVP binding to human Vasopressin V2 receptor coded HeLa cells by 50%2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
AID188449Urinary osmolality from urine collected from rat at 10 mg/kg1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID191024Diuretic effect was determined after peroral administration at a dose of 30 mg/kg in rats1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID217226Displacement of [3H]AVP from AVP-V1a receptor binding site in rat liver1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
AID224987Dose(mg/kg) required for a 3-fold increase in the 2-h urine volume over the control rats.1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
AID191022Diuretic effect was determined after peroral administration at a dose of 10 mg/kg in rats1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID188451Urinary osmolality from urine collected from rat at 3 mg/kg1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
AID703464Binding affinity to vasopressin V2 receptor2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID703459Antagonist activity at human vasopressin V2 receptor expressed in CHO cells assessed as inhibition of AVP-induced cAMP accumulation after 30 mins by TR-FRET based HTRF assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID703465Binding affinity to vasopressin V1a receptor2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346468Rat V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of biological chemistry, Nov-06, Volume: 273, Issue:45
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346468Rat V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1992British journal of pharmacology, Apr, Volume: 105, Issue:4
Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of biological chemistry, Nov-06, Volume: 273, Issue:45
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346455Rat V1A receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1799335Radioligand Binding Assay to HeLa Cells from Article 10.1016/s0968-0896(99)00101-7: \\7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressi1999Bioorganic & medicinal chemistry, Aug, Volume: 7, Issue:8
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.61)18.7374
1990's82 (50.00)18.2507
2000's52 (31.71)29.6817
2010's21 (12.80)24.3611
2020's8 (4.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.54 (24.57)
Research Supply Index5.16 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (4.85%)5.53%
Reviews19 (11.52%)6.00%
Case Studies3 (1.82%)4.05%
Observational0 (0.00%)0.25%
Other135 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]